Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis: Combining Real World and Clinical Trials for Totality of Evidence

被引：3
|
作者：
Khor, Yet H. [1 ,2 ,3 ]
机构：
[1] Univ Melbourne, Dept Resp & Sleep Med Austin Hlth, Melbourne, Vic, Australia
[2] Univ Melbourne, Inst Breathing & Sleep, Fac Med, Melbourne, Vic, Australia
[3] Monash Univ, Cent Clin Sch, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia
来源：
CHEST | 2021年 / 160卷 / 05期
关键词：
PIRFENIDONE;
D O I：
10.1016/j.chest.2021.07.033
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1589 / 1591
页数：3
相关论文
共 50 条
  • [41] Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?
    Suissa, Samy
    Assayag, Deborah
    EUROPEAN RESPIRATORY JOURNAL, 2021, 57 (03)
  • [42] Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
    Nayci, Sibel
    Polat, Demet
    Ozgur, Eylem Sercan
    Ozge, Cengiz
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [43] Persistence of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis: A Pulmonary Fibrosis Foundation Patient Registry Study
    Kulkarni, Tejaswini
    Flaherty, Kevin
    Gupta, Sachin
    Tu, Yi-Hsuan
    Case, Amy Hajari
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2025, 22 (01) : 165 - 168
  • [44] Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
    Pereira, Monica Pruss
    Branchini, Gisele
    Nunes, Fernanda Bordignon
    Altmayer, Stephan
    Hetzel, Guilherme Moreira
    Romero, Iveth
    Rubin, Adalberto Sperb
    Florian, Juliessa
    Nascimento, Douglas Zaione
    Watte, Guilherme
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2023, 49 (01)
  • [45] Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience
    Isshiki, Takuma
    Sakamoto, Susumu
    Yamasaki, Akira
    Shimizu, Hiroshige
    Miyoshi, Shion
    Nakamura, Yasuhiko
    Homma, Sakae
    Kishi, Kazuma
    RESPIRATORY MEDICINE, 2021, 187
  • [46] Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis
    Buendia-Roldan, Ivette
    Mejia, Mayra
    Selman, Moises
    ARCHIVOS DE BRONCONEUMOLOGIA, 2019, 55 (02): : 73 - 74
  • [47] ANTIFIBROTIC THERAPY INCREASES RISK OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Scullin, D.
    Barney, J.
    CHEST, 2020, 157 (06) : 157A - 157A
  • [48] Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study
    Adams, Colin J.
    Shapera, Shane
    Ryerson, Christopher J.
    Assayag, Deborah
    Johannson, Kerri A.
    Fell, Charlene D.
    Morisset, Julie
    Manganas, Helene
    Kolb, Martin
    Hambly, Nathan
    Cox, Gerard
    Khalil, Nasreen
    Marcoux, Veronica
    Wilcox, Pearce G.
    To, Teresa
    Sadatsafavi, Mohsen
    Halayko, Andrew J.
    Gershon, Andrea
    Garlick, Kristopher
    Fisher, Jolene H.
    RESPIRATORY MEDICINE, 2022, 191
  • [49] End-of-life of patients with idiopathic pulmonary fibrosis treated with antifibrotic therapy
    Sato, Makiko
    Koga, Yasuhiko
    Hachisu, Yoshimasa
    Takehara, Kazutaka
    Wakamatsu, Ikuo
    Shin, Yuki
    Saito, Haruka
    Yatomi, Masakiyo
    Tsurumaki, Hiroaki
    Sunaga, Noriaki
    Maeno, Toshitaka
    Hisada, Takeshi
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [50] A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia
    Khan, Mohammed Ayaz
    Al Ghamdi, Basma Al
    Alhamadi, Mohammed
    Rajendram, Rajkumar
    Alyami, Sami
    Al-Gamedi, Majed
    Al-Harbi, Abdullah
    Al-Jahdali, Hamdan
    ANNALS OF THORACIC MEDICINE, 2023, 18 (02) : 79 - 85
12345